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Background: Progressive multifocal leukoencephalopathy (PML) onset, caused by Polyomavirus JC (JCPyV) in
patients affected by immune-mediated diseases during biological treatment, raised concerns about the safety
profile of these agents. Therefore, the aims of this study were the JCPyV reactivation monitoring and the
noncoding control region (NCCR) and viral protein 1 (VP1) analysis in patients affected by different immune-
mediated diseases and treated with biologics.
Methods: We performed JCPyV-specific quantitative PCR of biological samples collected at moment of recruitment
(t0) and every 4 months (t1, t2, t3, t4). Subsequently, rearrangements’ analysis of NCCR and VP1 was carried out.
Data were analyzed using χ2 test.
Results: Results showed that at t0 patients with chronic inflammatory rheumatic diseases presented a JCPyV load
in the urine significantly higher (p≤0.05) than in patients with multiple sclerosis (MS) and Crohn’s disease (CD). It
can also be observed a significant association between JC viruria and JCPyV antibodies after 1 year of natalizumab
(p=0.04) in MS patients. Finally, NCCR analysis showed the presence of an archetype-like sequence in all urine
samples, whereas a rearranged NCCR Type IR was found in colon-rectal biopsies collected from 2 CD patients after
16 months of infliximab. Furthermore, sequences isolated from peripheral blood mononuclear cells (PBMCs) of
2 MS patients with JCPyV antibody at t0 and t3, showed a NCCR Type IIR with a duplication of a 98 bp unit and a
66 bp insert, resulting in a boxB deletion and 37 T to G transversion into the Spi-B binding site. In all patients, a
prevalence of genotypes 1A and 1B, the predominant JCPyV genotypes in Europe, was observed.
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Conclusions: It has been important to understand whether the specific inflammatory scenario in different immune-
mediated diseases could affect JCPyV reactivation from latency, in particular from kidneys. Moreover, for a more
accurate PML risk stratification, testing JC viruria seems to be useful to identify patients who harbor JCPyV but with
an undetectable JCPyV-specific humoral immune response. In these patients, it may also be important to study the
JCPyV NCCR rearrangement: in particular, Spi-B expression in PBMCs could play a crucial role in JCPyV replication
and NCCR rearrangement.
Keywords: JCPyV, q-PCR, JCPyV-specific antibodies, Multiple sclerosis, Natalizumab, Chronic inflammatory rheumatic
diseases, Crohn’s disease, anti-TNF, NCCR, VP1Background
The introduction of biologics in the management of
immune-mediated disease, such as multiple sclerosis
(MS), chronic inflammatory rheumatic diseases (CIRDs)
and Crohn’s disease (CD), has been recently associated
with the development of serious side effects, such as the
progressive multifocal leukoencephalopathy (PML) onset,
caused by human Polyomavirus JC (JCPyV) reactivation
from oligodendrocytes [1]. JCPyV is a neurotropic double-
stranded DNA virus isolated in 1971 from the brain of a
patient with Hodgkin’s disease [2]. The 50–90% of adult
human population seem to be seroconverted to the virus,
with 19–27% of these people shedding JCPyV in their
urine [3,4]. The JCPyV genome is composed of early and
late regions that are physically separated by the non-
coding control region (NCCR). The early region encodes
for proteins (TAg, tAg and T primes) involved in viral
gene regulation and replication, whereas the late genes
encode for the viral capsid proteins (VP1, VP2 and VP3)
[5]. The coding regions are well conserved and they are
associated with various viral subtypes, which can be found
in different geographical areas [6]. Conversely, the NCCR
sequence is hyper-variable and contains neurotropic and
neurovirulent determinants. The rearranged NCCR se-
quences, forming during immunosuppression, correlate
with poor clinical outcome in PML patients. PML is a
demyelinating disease of the brain, originally recognized
as a rare complication of hematological malignancies or
systemic inflammatory disorders. However, a dramatic 50-
fold increase in the PML incidence occurred with the HIV
epidemic [5,7]. Recently, cases of PML were also observed
in patients under treatment with biologics, including
monoclonal antibodies (mAbs). In particular, the mAb
natalizumab (Tysabri®; Biogen Idec, Elan Pharmaceuticals)
that targets the very late antigen-4 (VLA-4), a cell adhe-
sion molecule, to prevent extravasation of inflammatory T
cells into tissues, have been associated with PML [8].
Furthermore, several cases of demyelinating events of the
nervous system have been reported for anti-tumor necro-
sis factor (TNF) agents, such as infliximab (Remicade®;
Centocor Ortho Biotech), in CD, severe forms of plaque
psoriasis, rheumatoid arthritis (RA) and spondyloarthritis[9-11]. Considering the significant impact of PML onset
on the development of biologic agents, it is imperative to
assess the risk of PML associated with these therapies in
order to achieve a well-informed risk/benefit decision-
making. Recently, it was calculated that the risk of PML
was of 11.1 cases per 1000 patients (95% CI, 8.3 to 14.5)
among natalizumab-treated individuals who had all three
main risk factors: presence of anti-JCPyV antibodies, prior
use of immunosuppressants, and natalizumab treatment
for 25 to 48 months [12-14]. It was also hypothesized that
natalizumab could block lymphocyte trafficking through
the blood-brain barrier, resulting in a decrease of immu-
nosurveillance that allows JC virus reactivation from
latency [15]. Moreover, possibly as a consequence of a
blocking effect of this drug on the VLA4/vascular cell
adhesion molecule 1 (VCAM-1) interaction, a rapid egress
of CD34+ cells from the bone marrow (BM) was observed
[16-18]. To date, there are no methods that can reliably
predict which patients have a higher risk of developing
PML, and no clear-cut associations can be established
between JCPyV DNA in the blood or urine and PML
[18-22]. In the attempt to bypass this problem, a new
assay (STRATIFY JCV®) was suggested to be a sensitive
tool to identify JCPyV seroconverted patients [23].
Complementary tests of JCPyV DNA in urine were also
indicated as being useful for the stratification of risk of
PML in patients [24], since the detection of urinary viral
DNA identifies JCPyV infected subject when antibody are
still undetectable [25].
Conversely, among patients with CIRDs, 34 confirmed
and biological agents-related cases of PML have been
reported on the Food and Drug Administration Adverse
Event Reporting System (FDA AERS) database, and 17
of them had a diagnosis of systemic lupus erythematosus
(SLE). These results are consistent with previous obser-
vations [26-29] that patients with SLE appear to have a
particular susceptibility to the development of PML,
respect to other patients with CIRDs. Moreover, six
reports described PML occurrence in CIRDs patients
treated with anti-TNF therapies, although all these cases
were confounded by treatment with other immunosup-
pressive agents. Consequently, the rarity of the association
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dence against a causal role of anti-TNF therapy in the
development of PML. However, the recent report of an
apparently non-confounded case of PML in an RA patient
treated with infliximab calls for caution [30].
To date, the precise mechanism by which these treat-
ments may have facilitated the pathogenesis of PML is a
matter of debate, but likely it is based on leukocytes
inability to traffic to the sites of JCPyV reactivation and
infection, and on trafficking of JCPyV latently infected B
cells and/or haematopoietic precursors CD34+ between
the BM and the brain. JCPyV activity in sites of persist-
ence, and ultimately development of PML, is restricted
by viral NCCR variation and activation of gene expres-
sion from the NCCR by essential cellular factors [31].
Since JCPyV latency is associated with cells undergoing
haematopoietic development, it is probable that transcrip-
tion factors reported as lymphoid specific regulate JCPyV
gene expression. One such factor, Spi-B, is up-regulated in
peripheral blood mononuclear cells (PBMCs) in response
to treatment with natalizumab. Spi-B is also involved in
differentiation and maturation of B cells and it is ex-
pressed at high levels in developing and mature B cells.
Recently, Spi-B has been reported to bind the NCCR of
the PML-associated Mad-1 and Mad-4 but not the non-
pathogenic archetype CY, in specific binding sites adjacent
to TATA boxes. The active Spi-B-binding site of Mad-1/
Mad-4 differs from that of CY by a single nucleotide
mutation, strongly affecting the early viral gene expression
[32]. Importantly, similar mutation that creates active
Spi-B-binding sites adjacent to the TATA box of arche-
type-like JCPyV have been described by our research
group in intestinal biopsies of CD patients treated with
infliximab, suggesting that this mutation is supported
during dissemination in the host [33].
Therefore, in order to understand the JCPyV reactiva-
tion trend in patients with immune-mediated diseases
treated or candidates to treatment with biologics, we
have enrolled three cohorts: a cohort of MS patients
(Cohort1) treated with natalizumab, a cohort of
CIRDs patients (Cohort2) treated with conventional
immunosuppressants and candidates to biologics, and
a cohort of CD patients (Cohort3) treated with
infliximab. The first aims of this study have been the
JCPyV detection by quantitative Real Time PCR
(q-PCR) in several samples collected from the three
cohorts at specific sampling times. Subsequently, we
have performed the analysis of the possible rear-
rangements of JCPyV NCCR, in order to detect cellu-
lar transcription factors binding site mutations, and
the study of JCPyV VP1 sequence, in order to define
a possible correlation between a specific JCPyV geno-
type/subtype and immune-mediated diseases and/or
biological treatments.Results
Clinical outcome
A clearly positive outcome of the study was that no PML
cases developed during the follow-up period in any cohort.
Regarding the Cohort1, clinical relapses during the 12-
month period of therapy were observed in only 1/21 MS
patients. However, only eighteen patients reached a
follow-up of 12 months, because one patient suspended
natalizumab for allergic reaction and two patients
showed poor compliance. Moreover, one patient suspen-
ded the biological therapy for uterine cancer and
papillomatosis after 11 months of natalizumab infusions,
and another one did not perform two natalizumab infu-
sions because of Escherichia coli urinary infection
(Table 1). The clinical efficacy of natalizumab was con-
firmed by the observation that the Kurtzke Expanded
Disability Status Scale (EDSS) [34] remained stable in all
18/21 patients (86%).
Regarding the Cohort2, the demographic and clinical
characteristics of the CIRDs patient are shown in Table 2.
For this cohort, we collected only the baseline (t0)
patients’ features and the JCPyV DNA q-PCR results in
urine, plasma and PBMCs samples obtained at t0. About
baseline (t0) JCPyV q-PCR detection, we observed JCPyV
DNA in 14/22 urine samples with this distribution among
the three specific CIRDs considered: 7 in RA, 3 in anky-
losing spondylitis (AS) and 4 in psoriatic arthritis (PsA)
(Table 3). Plasma and PBMCs samples were all negative
for JCPyV DNA detection at t0. No significant differences
were found between PsA and RA patients for gender, age,
patient and physician global assessment, Health Assess-
ment Questionnaire (HAQ) score, Disease Activity Score
with a 28-joint count C-reactive protein-related (DAS28-
CRP) and erythrocyte sedimentation rate-related (DAS28-
ESR). Moreover, no significant differences were observed
concerning the type of concomitant Disease Modifying
Anti-Rheumatic Drugs (DMARDs) and disease duration,
although disease duration was numerically, but not signifi-
cantly, higher in RA patients (Table 3).
Regarding the Cohort3, eighteen patients (10 males, 8
females; mean age ± standard deviation (std. dev.): 14.61 ±
4.36 years) with refractory active CD and thus aimed at
infliximab treatment, were enrolled. After enrollment,
clinical characteristics of CD disease were recorded and
clinical activity, measured with the Pediatric CD Activity
Index (PCDAI), was > 30 (Table 3). During 16-months
follow up, improvements were observed in each patient
based on the physician's global evaluation of amelioration
compared with baseline (data not shown).
Baseline (t0) JCPyV DNA detection in plasma and urine
samples
Regarding the baseline (t0) JCPyV DNA detection by q-
PCR in plasma samples, collected from the three
Table 1 JCPyV-DNA q-PCR in plasma, urine and PBMCs samples of 21 MS patients in 1-year follow-up
Plasma*,** Urine*,** PBMCs*,**
Pts. STRATIFY JCV® t0† t0 t1 t2 t3 t0 t1 t2 t3 t0 t1 t2 t3 STRATIFY JCV® t3†
MS 1 Pos 2.70 3.26 3.03 Pos
MS 2‡ Pos 2.85 2.67 / / / / 2.56 / / Pos
MS 3 Neg 3.7 3.48 6.01 3.86 Pos
MS 4‡ Neg 3.15 3.32 Pos
MS 5‡ Neg 4.1 4.58 7.30 6.18 Pos
MS 6 Neg 2.68 Pos
MS 7 Neg 5.47 Pos
MS 8 Neg 4.74 Pos
MS 9 Neg Neg
MS 10 Neg Neg
MS 11 Neg 3.77 Neg
MS 12 Neg 3.72 Neg
MS 13 Neg Neg
MS 14 Neg Neg
MS 15 Neg Neg
MS 16 Neg Neg
MS 17 Neg Neg
MS 18‡ Neg 3.00 Neg
MS 19‡ Neg / / / / / / Neg
MS 20‡ Neg / / / / 6.04 / / Neg
MS 21 Neg Neg
Median JCPyV load** 2.77 2.67 3.26 3.00 3.90 4.03 6.03 4.74 3.14 3.03
p value§ 0.04
pos: positive; neg: negative.
* 78 urine, 78 plasma and 78 PBMCs samples were collected at baseline (t0) and after 4 (t1), 8 (t2), and 12 (t3) months of therapy.
† 2-step virus-like particle-based enzyme-linked immunosorbed assay (ELISA) (STRATIFY JCV®) was performed at t0 and t3, to detect specific anti-JC virus
antibodies in serum of the 21 enrolled subjects.
** JCPyV loads values are expressed as log10 genome equivalent (gEq)/mL in urine and in plasma, and as log10 gEq/106 cells in PBMCs and they are indicated
in boldface.
§ By χ2 test: positive STRATIFY JCV® patients after 1-year of natalizumab treatment vs negative STRATIFY JCV® patients after 1 year of natalizumab treatment. p
value < 0.05 only for JCPyV DNA positive urine samples.
‡ patient MS2 suspended natalizumab for allergic reaction; patients MS19 and MS20 showed poor compliance; patient MS18 suspended the biological therapy for
uterine cancer and papillomatosis after 11 months of natalizumab infusions; patient MS4 did not perform 2 natalizumab infusions because of Escherichia coli
urinary infection; patient MS5 showed clinical relapse during follow up.
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log10 (range)] in 2/21 MS patients [2.77 gEq/mL (2.70-
2.85)], in none CIRDs patients and in 6/18 CD patients
[4.93 gEq/mL (3.06-6.58)]. Moreover, only 1/19 healthy in-
dividual presented JCPyV DNA in plasma (2.83 gEq/mL).
Comparing the JCPyV DNA results obtained in plasma,
we did not observe significant difference among the three
cohorts, maybe because the number of patients enrolled
was too small. On the other hand, regarding the baseline
(t0) JCPyV DNA detection in urine samples, collected
from the three Cohorts, we found JCPyV load [median
log10 (range)] in 2/21 MS patients [3.90 gEq/mL (3.70-
4.10)], in 14/22 CIRDs patients[7.21 gEq/mL (4.15-8.13)]
and in 6/18 CD patients [6.30 gEq/mL (4.85-8.85)].
Moreover, 5/19 healthy individuals showed JCPyV DNAin urine [5.75 gEq/mL (3.54-8.43)]. Comparing these data
of JC viruria, we observed that CIRDs patients showed a
JC viruria significantly higher than that observed in
patients with MS or with CD (p < 0,05) and in healthy
individuals (Figure 1). These data could lead us to con-
clude that the CIRDs inflammatory scenario could favor
the JCPyV shedding in the urine but not the JC viremia
appearing. Finally, no patient or healthy individual showed
JCPyV DNA detectable in PBMCs samples at t0.
Anti–JCPyV antibodies in serum and longitudinal
assessment of JCPyV DNA in urine, plasma and PBMCs
samples collected from MS patients
The anti-JCPyV antibodies ELISA assay (STRATIFY
JCV®) was performed only at the study enrollment (t0)
Table 2 Main features of patients with chronic
inflammatory rheumatic diseases (CIRDs) (n=22)
Characteristics
Male/Female (n) 7/15
Age (years; median/range) 53/36-79
Diagnosis: PsA/RA/AS 11/8/3
Symptoms onset (months ago; median/range) 75/24-420
CRP (mg/dl; median/25th-75th percentile) 0.09/0-1.225
ESR (mm/h; median/25th-75th percentile) 18.5/13.25-33.75
HAQ (0-3; mean/SD) 1.275 ± 0.82
DAS28-ESR (mean/SD)* 4.6 ± 1
DAS28-CRP (mean/SD)* 4.05 ± 0.99
Physician’s global assessment of disease activity
(0-100 mm, VAS; mean/SD)*
56.3 ± 28.2
Patient’s global assessment of disease activity
(0-100 mm, VAS; mean/SD)*
59.6 ± 30.5
BASDAI (1-10; mean/SD)** 7.1 ± 3
Concomitant DMARDs (n/%) 10/45.4
Concomitant DMARDs and glucocorticoids (n/%) 4/18.2
Concomitant glucocorticoids (n/%) 10/45.4
No concomitant treatment (n/%) 6/27.3
PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosing spondylitis;
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ: Health
Assessment Questionnaire; SD: standard deviation; DAS28: 28-joint Disease
Activity Score; VAS: visual analog scale; BASDAI: Bath Ankylosing Spondylitis
Diseease Activity Index; DMARDs: disease modifying anti-rheumatic drugs.
*For patients with RA and PsA.
**For patients with AS.
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samples of the 21 enrolled MS patients. At t0 only 2/21
(9%) individuals resulted seropositive for JCPyV. At t3,
the number of positive STRATIFY JCV® patients moved
from 2 to 8 (Table 1). We found a statistical significantTable 3 Baseline (t0) features and JC viruria of 21 MS, 18 CIRD
Pathology Cohort1
MS PsA
Female / Male 10 / 11* 5 / 6





Age† 37 (19–49) 53 (46–72) 53.
Symptoms onset, months ago† 72 (12–300) 60 (24–312) 108
Disease activity†§ 2 (0–4)§ 4.11 (2.46–4.61)§ 4.18
MS: multiple sclerosis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosin
rheumatic diseases.
† For each category the median values (range) are indicated. In particular JCPyV loa
plasma, and as log10 gEq/106 cells in PBMCs.
§: Disease Activity is indicated by scale, score or index specific for each disease asse
This scale ranges from 0 (normal neurological examination) to 10 (confined to bed)
to C-reactive protein (DAS28-CRP) is used, with a high score indicating more active
(BASDAI) is used. This index ranges from 0 (no activity) to 10 (maximum activity); fo
(score ≤10: inactive disease; 10–30: mild disease; >30: moderate to severe disease).
* At t0, 1 patient (out of the 21 multiple sclerosis patients enrolled) do not perform
‡ nd: no data.difference between positive and negative STRATIFY
JCV® patients regarding the number of months from
symptoms onset: positive STRATIFY JCV® patients have
a number of months from symptoms onset higher than
those of negative STRATIFY JCV® patients (mean
months from symptoms onset ± std dev: 114 ± 104.22 vs
87.69 ± 80.26) (p < 0.05) (data not shown). On the other
hand, JCPyV DNA was detected by q-PCR in urine,
plasma and PBMCs samples collected at baseline (t0)
and after 4 (t1), 8 (t2), and 12 (t3) months of
natalizumab infusions. From data obtained JCPyV DNA
was observed in plasma in 5/21 cases, in urine in 7/21
individuals and in PBMCs in 3/21 cases (Table 1).
Comparing the results of positive STRATIFY JCV® with
JCPyV DNA q-PCR data obtained in plasma, PBMCs and
urine collected from MS patients during 1 year of
natalizumab treatment, we observed that 2 patients with a
positive STRATIFY JCV® at t0, showed both viremia at t0
and then 1 at t1 and one at t2, but no viruria. Moreover, in
the same 2 patients, JCPyV DNA was also detected in
PBMCs at t3 and t1 (Table 1). Conversely, in the other 6
patients with positive STRATIFY JCV® after one year of
treatment with natalizumab, 2 patients showed viruria all
along the follow-up but not viremia; 3 patients presented
viruria only at t3 and 1 of them showed also viremia at t3;
finally, 1 patient showed only viremia at t3. No significant
differences were observed in JCPyV viral load in plasma
(log10 gEq/ml) when baseline (t0) results (median: 2.77,
range: 2.70-2.85) were compared to data obtained at the
different time of follow-up (t1: 2.67; t2: 3.26; t3: 2.91, 3.15-
2.68) (Table 1 and Figure 2A). Conversely, a significant
difference was observed in JCPyV viral load in urine
(log10 gEq/ml) when baseline (t0) results (median:
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5 (36–79) 47 (38–54) 53 (36–79) 15 (8–22) 35 (25–47)
(52–156) 120 (36–420) 75 (24–420) nd‡
(2.50–5,89)§ 7,3 (4–10)§ > 30§
g spondylitis; CD: Crohn's disease; CIRDs: chronic inflammatory
ds values are expressed as log10 genome equivalent (gEq)/mL in urine and in
ssed: for Cohort1 MS, Kurtzke Expanded Disability Status Scale (EDSS) is used.
; for PsA and RA (Cohort2), Disease Activity Score with a 28-joint count related
disease; for AS (Cohort2), Bath Ankylosing Spondylitis Disease Activity Index
r Cohort3 CD, Pediatric Crohn's Disease Activity Index (PCDAI) is used
the urine and blood sampling.
Figure 1 Comparison of baseline (t0) JC viruria in 21 MS, 18 CIRDs
and 22 CD patients. JCPyV DNA [(median log10 JCPyV load (range)]
was found in 2/21 multiple sclerosis patients [3.90 gEq/mL (3.70-4.10)],
in 14/22 CIRDs patients [7.21 gEq/mL (4.15-8.13)] and in 6/18 CD
patients [6.30 gEq/mL (4.85-8.85)]. Moreover 5/19 healthy individuals
showed JCPyV DNA in urine [5.75 gEq/mL (3.54-8.43)]. Comparing
these data of JC viruria, we observed that CIRDs patients presented a
JC viruria significantly higher than that presented by patients with MS
or with CD and by healthy individuals. JCPyV loads values are
expressed as log10 genome equivalent (gEq)/mL. Comparisons were
performed using non parametric Mann–Whitney U-test and statistically
significant p values (< 0.05) were indicated.
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and Figure 2B).
On the other hand, among the 13 patients with
persistent negative STRATIFY JCV® after 1 year of
natalizumab treatment, 1 patient showed viremia only at
t3, 2 patients presented viruria only at t2, and 1 patient
showed JCPyV DNA detectable in PBMCs samples at t1.
The remaining 9 negative STRATIFY JCV® patients werenegative to DNA detection in plasma, PBMCs and urine
samples all along the follow-up.
It can also be observed a significant association
between JC viruria at t3 and a positive STRATIFY JCV®
after 1 year of natalizumab respect to the 13 patients
with persistent negative STRATIFY JCV® after 1 year of
natalizumab treatment (p = 0.04) (Table 1).
Finally, in this cohort JCPyV load in urine was always sig-
nificantly higher than that detected in plasma (p < 0.001)
and in PBMCs samples (p = 0.02). No difference was
observed between the JCPyV loads detected in plasma
(median: 2.85, range: 2.67-3.26) and PBMCs samples
(median: 3.03, range: 2.56-3.72) respectively (p = 0.83)
(data not shown).
STRATIFY JCV® results and longitudinal analysis of
JCPyV DNA detection in plasma, urine and PBMCs
samples in this cohort were shown in Table 1.Longitudinal assessment of JCPyV DNA in urine and
plasma samples and intestinal biopsies collected from CD
patients
The follow-up of the JCPyV DNA detection in urine and
plasma samples and intestinal biopsies collected at
baseline (t0) and after 4 (t1), 8 (t2), 12 (t3) and 16 (t4)
months of infliximab treatment was performed by q-
PCR in Cohort3.
Results on plasma samples showed the presence of
JCPyV in 6/18 CD patients at t0. At t1 in Cohort3, the
patients with viremia were 7/18, whereas at t2 and t3,
we observed a decrease of the JCPyV positive plasma
specimens up to 5/18 and this number remained con-
stant at t4 (Table 4). These data showed that the number
of patients with JC viremia in Cohorts 3 remain constant
during the follow-up (p > 0.05). Comparing the JC viral
loads in plasma at each time of follow-up (Table 4), we
did not observe a significant difference (p > 0.05), as
shown in Figure 2A.
The viral DNA was found in 6/18 urine at t0 with a me-
dian JCPyV load (range) of 6.30 gEq/mL (4.85-8.85) and
four months later (t1), the number of patients with viruria
increased up to 10/18 (median: 6.12 gEq/mL; range: 3.17-
8.37), whereas at t2, a reduction of this number was ob-
served (6/18). Finally, we found JCPyV in 6 urine out of
18 CD patients both at t3 and at t4 (Table 4). No signifi-
cant difference in the number of patients with JC viruria
was found during the follow-up (p > 0.05). Comparing the
urinary JCPyV loads obtained at each time of follow-up,
we observed that viruria significantly increased in the
patients treated with infliximab at t3 respect to the
value obtained at t0 (p = 0.03). In fact, at t3 the me-
dian JCPyV load reached the value of 7.47 log gEq/
mL (range: 5.63-9.39) respect to the baseline value
of 6.30 gEq/mL (range: 4.85-8.85) (Figure 2B).
Figure 2 Comparison of JC viremia and viruria in 1-years follow-up: 21 MS vs 18 CD patients. (A.) Comparing JC viremia follow up of MS vs
CD patients, the viremia of CD patients during the follow-up is numerically higher than that observed in MS patients, although we did not find a
statistically significant difference (p = 0.07). (B.) Comparing JC viruria follow up of MS patients treated with natalizumab vs CD patients treated
with infliximab, we observed a persistent viruria both cohorts. However the JC viruria of patients treated with infliximab, was significantly higher
than that of patients treated with natalizumab only at t1 (p = 0.01) and at t3 (p = 0.05). Moreover a significant difference between the JC viruria
detected at t0 and at t3 in both cohorts was also reported. JCPyV load values are expressed as log10 genome equivalent (gEq)/mL. JCPyV
load values of MS cohort and CD cohort are reported in table 1 and table 4, respectively. Comparisons were performed using non parametric
Mann–Whitney U-test and p values <0.05 were considered statistically significant. t0: baseline values. t1, t2 and t3: 4, 8 and 12 months of
therapy, respectively.
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ficantly lower than that observed in urine (p < 0.001)
(data not shown).
Concerning JCPyV detection in the ileal and colon-
rectal biopsies in the cohort of CD, results showed that
at t0 JCPyV was found in 10/18 ileal specimens and in
8/18 colon-rectal biopsies. At t3, we found JCPyV in 7/
18 ileal biopsies and in 4/18 colon-rectal biopsies. At t4
the number of JCPyV-positive ileal specimens decreased
to 4/18, whereas the number of JCPyV-positive colon-
rectal biopsies remained constant (Table 4). From these
data we observed a numerical decrease in the number of
patients with JC viral load in both colon-rectal and ileal
biopsies after 16 months of treatment with infliximab,
although this decrease was not statistically significant
(p > 0.05). Moreover, a constant JC viral load value
was found in both type of biopsies during the follow-up
and the JCPyV load in ileal biopsies was shown to be
numerically higher that that observed in colon-rectalbiopsies, although the difference was not statistically
significant (p = 0.09) (data not shown).
JC viruria and viremia 1 years follow-up: MS patients
treated with natalizumab vs CD patients treated with
infliximab
Comparing the JCPyV loads in plasma samples obtained
from MS and CD patients during the follow up, we
observed that JC viremia in CD patients is numerically
higher than that of MS patient, although we did not find
a statistically significant difference (p = 0.07), probably
because the number of patients enrolled was too small
(Figure 2A).
Conversely, comparing the JCPyV loads in urine
samples of MS patients treated with natalizumab with
that of CD patients treated with infliximab, we observed
a persistent viruria in both Cohorts, although the
JCPyV viruria of patients treated with infliximab was sig-
nificantly higher than that of patients treated with
Table 4 JCPyV DNA detection in samples collected from 18 CD patients during 1 year of infliximab
Plasma (log10 gEq/mL)
Time* t0 t1 t2 t3 t4
JCPyV+ / JCPyV- 6 / 12 7 / 11 5 / 13 5 / 13 5 / 13
median JCPyV load (range) 4.93 5.30 3.08 3.63 4.24
(3.06-6.58) (3.78-5.59) (2.58-6.11) (2.76-5.35) (3.92-5.54)
Urine (log10 gEq/mL)
JCPyV+ / JCPyV- 6 / 12 10 / 8 6 / 12 6 / 12 6 / 12
median JCPyV load (range) 6.30 6.12 5.85 7.47 6.70
(4.85-8.85) (3.17-8.37) (4.30-8.15) (5.63-9.39) (3.85-7.85)
Ileum (log10 gEq/106 cells)
JCPyV+ / JCPyV- 10 / 8 7 / 11 4 / 14
median JCPyV load (range) 4.29 5.85 5.07
(3.54-6.57) (4.34-8.48) (3.81-7.15)
Colon rectum (log10 gEq/106 cells)
JCPyV+ / JCPyV- 8 / 10 4 / 14 4 / 14
median JCPyV load (range) 3.66 4.85 4.25
(3.10-4.67) (3.52-6.08) (3.38-4.78)
*We collected 90 plasma and 90 urine samples from CD patients at the following times of sampling: at the time of recruitment (t0) and at 4, 8, 12 and 16 months
from t0 (t1, t2, t3, and t4 respectively). 54 ileal and 54 colon–rectal biopsies were recruited at t0, t3 and t4 within the same cohort.
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(Figure 2B).
JCPyV VP1 sequence analysis
We performed the JCPyV VP1sequence analysis by auto-
matic sequencing of PCR product corresponding to
JCPyV VP1 regions, in order to identify JCPyV genotype
featuring our enrolled Cohorts. In all 3 Cohorts we
observed a prevalence of genotypes 1A and 1B and it is
also important to note that in each patient we never
observed a co-infection with different strains of JCPyV.
In particular, among the 21 MS patients, we observed
JCPyV Type 1A, Type 1B and Type 4 in 10, 9 and 2
individuals, respectively. Moreover, JCPyV Type 1A was
also observed in 10/18 CD patients and 9/22 CIRDs
patients, whereas the other individuals (8/18 CD patients
and 13/22 CIRDs patients) showed a JCPyV genotype 1B
(data not shown).
JCPyV NCCR sequence analysis
The NCCR forms were classified into four types as pre-
viously described [35]. Type I-S has a single 98 base-pair
(bp) unit, also known as sequence composed of boxA
(25 bp), boxC (55 bp) and boxE (18bp). Type I-R has
repeats of this 98 bp unit, with various deletions, as seen
in the JCPyV Mad-1 (GenBank no: J02227) and Mad-4
[36,37] strains; both of these types have no 23- and/or
66 bp inserts, also known as boxB and boxD, respect-
ively (Figure 3A). Conversely, type II-S has a single 98
bp unit and one 23- and one 66 bp insert, as seen in the
archetype CY [38], also known as sequence composed ofboxes A (25 bp), B (23 bp), C (55 bp), D (66 bp) and E
(18 bp) (Figure 3B). Finally, type II-R has repeats of this
98 bp unit and inserts with various mutations, also
called rearranged NCCRs. Furthermore, in all NCCR
sequences a 69 bp sequence is always present, called
boxF, starting with the 207 nucleotide considering the
nucleotide numbering based on PML-associated variant
Mad-1 NCCR sequence [36].
In MS patients, the archetypal variant type IIS has
been found in all samples analyzed, with the exception
of 2 rearranged NCCR sequences type IIR isolated from
PBMCs of the only 2 MS patients, resulted STRATIFY
JCV® positive t0 and t3. These rearranged NCCR showed
a duplication of a 98bp unit and a 66bp insert, resulting
in a boxB deletion with a 37 T to G nucleotide trans-
version (37 T→G) into the Spi-B binding site, followed
by a duplication of the boxC and boxD insertion
(Figure 3C and Table 5B).
Moreover, all sequences found in the 14 urine samples
with JC viruria and collected at t0 from CIRDs patients,
showed archetype structure type IIS (Figure 3B), with
only a 217 G to A nucleotide transition (217 G→A) in
the boxF.
Regarding the sequences analysis of NCCR found in
plasma, urine and intestinal biopsies of patients with CD
treated with infliximab, the 72% of all sequences ana-
lyzed showed an archetypal structure type IIS. A NCCR
Type IIS with a 37 T→G within Spi-B binding site, and
a 217 G→A in the boxF, was found in 8/28 (29%)
plasma, 7/21(33%) ileal and 5/16 (32%) colon-rectal










Figure 3 (See legend on next page.)
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Figure 3 JCPyV NCCR sequence analysis in 21 MS and 18 CD patients. (A.) Type IR has repeats of 98bp unit, also known as sequence
composed by boxA (25 bp), boxC (55 bp) and boxE (18 bp), as seen in the JCPyV prototype Mad-1 [35,36], without 23- and/or 66-bp inserts, also
known as boxB and boxD respectively. (B.) Type IIS has a single 98 bp unit, with one 23- and one 66-bp insert, as seen in the archetype CY
[35,38]. The NCCR type IIS is also known as sequence composed by boxes A, B, C, D and E. Each 98bp unit is represented by an open box. The
23 bp and 66 bp inserts are represented as open boxes labeled “23 bp” and “66 bp,” respectively. The nucleotide numbering of Mad-1 NCCR is
indicated in black bold font, whereas the nucleotide numbering of CY NCCR is reported in grey bold font. In all NCCR sequences is present a
69 bp sequence, called box F, starting from nucleotide 207. (C.) A NCCR Type IIS was found in 8/28 plasma, 7/21 ileal and 5/16 colon-rectal
biopsies, collected from CD patients. A NCCR Type IIR with a boxD deletion was found in 4/21 ileal and 1/16 colon-rectal biopsies. Another NCCR
Type IIR, composed by a duplication of a 98 bp unit and a 66 bp insert, was found in 2/3 PBMCs of 2 MS patients. Finally, a NCCR Type IR
sequence was found in 2/16 colon-rectal biopsies. Dotted lines represent deletions or regions not present. Asterisks represent single nucleotide
point mutations or deletions. Black bold letters indicate nucleotides and underlined letters in grey bold font indicate the relative point mutations.
The types of NCCR are indicated. The main cellular factor binding sites are also reported. Ori: replication’s origin.
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deletion was found in 4/21 (20%) ileal and 1/16 (6%)
colon-rectal biopsies. Finally, a rearranged JCPyV NCCR
Mad-1-like type IR sequence, composed by repeats of
truncated 98bp unit, resulting in deletion of the boxB
followed by a tandem repeat sequence constituted by a
partial boxC duplication, a boxD deletion and an integral
boxE, was found in 2/16 (12%) colon-rectal biopsies. All
these rearranged sequences were found only in the
intestinal biopsies and plasma samples collected at t3
and t4 from seven pediatric CD patients treated with
infliximab. All these seven patients presented a value
of PCDAI> 40 at t0. The rearranged JCPyV NCCR
Mad-1-like type IR sequence was instead found at t4
(after 16 months of infliximab treatment) in 2 colon
rectal biopsies collected from 2/7 patients indicated
above (Figure 3C and Table 5A).Table 5 NCCR analysis in samples collected from Crohn’s Dise
A. Crohn’s Dise
Samples N° JCPyV positive samples N° archetype* (%) (IIS)†
Urine 34 34 (100%)
Plasma 28 20 (71%)
Ileum 21 10 (47%)
Colon-rectum 16 8 (50%)
Total (%) 99 72 (72%)
B. Multiple Scler
Samples N° JCPyV positive samples N° archetype* (%) (IIS)†
Urine 13 13 (100%)
Plasma 7 7 (100%)
PBMC 3 1 (33%)
Total (%) 23 21 (91%)
* JCPyV archetype CY [38] with random occurrence of few point mutations and con
** T to G transversion at position nucleotide number 37 in the box A within Spi-B b
boxF considering the nucleotide numbering based on non-pathogenic JCPyV arche
† Jensen and Major (2001) NCCR forms classification is also reported [35].Discussion
In the last decades, PML onset during treatment with
biological agents has made imperative to assess the risk
of PML associated with these therapies, in order to
achieve a well-informed risk/benefit decision-making.
However, the epidemiology of PML in such settings
remained difficult to define, because PML is rare and
likely underdiagnosed and because the nature of the risk
associated with biological therapy is widely debated [29].
Firstly, it has been important to understand whether the
specific inflammatory scenario of different immune-
mediated diseases could affect the JC virus reactivation
from its sites of latency. Several immune-mediated
diseases are characterized by common alterations of the
cell T helper (Th) 1 versus Th2 and interleukin (IL) -12/
TNF versus IL-10 balance. In particular, in RA, MS and
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stant G to A transition at position nucleotide number 217 in the boxF.
inding site, and G to A transition at position nucleotide number 217 in the
type CY [38].
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associated with a Th2 shift and an excessive production
of IL-10 [39]. In fact, it was over-documented that SLE
patients appear to have a particular susceptibility to the
development of PML [26-29]. In addition, MS patients
with natalizumab-associated PML were distinguished
from all other subjects because they had JCPyV-specific
CD4+ T cell responses uniquely dominated by IL-10
production. Thus, changes in T cell-mediated control of
JCPyV replication may be a risk factor for developing
PML [13]. Moreover, in MS and CIRDs patients, gluco-
corticoids treatment is associated with increased plasma
IL-10 secretion [39]. These observations suggested that
virus is kept at bay by cell-mediated immunity in healthy
subjects, although JCPyV-specific antibodies are present
in about 58% of healthy individuals [40-42]. On the basis
of our results, comparing the JCPyV DNA detection in
plasma at the baseline, we did not observe significant
differences among the three Cohorts, probably because
the number of patients enrolled was too small. Con-
versely, comparing baseline JCPyV DNA detection in
urine samples, we observed that CIRDs patients showed
a JC viruria significantly higher than that observed in
patients with MS or with CD (p<0.05) and in healthy
individuals. These data could lead us to conclude that
the CIRDs inflammatory scenario could favor the JCPyV
shedding in the urine but not the JC viremia appearing.
Taking into account the results obtained and the
assumptions previously made, we also observed that 7
out of 14 CIRDs patients, who shed JCPyV in the urine,
underwent concomitant therapy with glucocorticoids,
whereas no MS patients were treated with glucocor-
ticoids before natalizumab treatment. Moreover, it was
also well known that the standard treatment of CD
patients includes the use of budesonide and prednisone.
Therefore, it is reasonable to assume that the use of
glucocorticoids, as concomitant therapy in the treatment
of immune-mediated diseases, could have favored the
JCPyV reactivation in the kidney. In fact, as previously
mentioned, treatment with glucocorticoids is associated
with increased plasma IL-10 secretion and thus with an
imbalance of cell mediated immunity, that finally may
have determined the JCPyV shedding in urine, especially
in CIRDs patients. However, this assumption requires a
further systematic investigation on correlation between
use of glucocorticoids and prevalence of JC viremia
and viruria in patients affected by immune-mediated
diseases.
To date, there are no methods that can reliably predict
which patients have a higher risk of developing PML
and no clear-cut associations can be established between
JC viremia and viruria and PML. In the attempt to
bypass this problem, a new assay (STRATIFY JCV®) was
suggested to be a sensitive tool to identify JCPyVseroconverted patients [23], especially among MS
patients treated with natalizumab. Therefore, regarding
the monitoring of the asymptomatic reactivation of
JCPyV in peripheral blood and urine of MS patients
treated with natalizumab for 1 year, some authors
[43,44] reported the frequent detection of JCPyV reacti-
vation in the urinary tract after therapy. In agreement
with these authors, in this study a significant difference
was observed in JCPyV viral load in urine when baseline
(t0) results were compared to data obtained at t3 (p = 0.05).
It can also be observed a significant association between JC
viruria at t3 and a positive STRATIFY JCV® after 1 year of
natalizumab respect to the 13 patients with persistent
negative STRATIFY JCV® (p = 0.04). As other Authors
have suggested [24], complementary tests of JCPyV DNA
in urine seems to be useful to stratify the PML risk, since
the detection of urinary viral DNA identifies JCPyV
infected subject when antibodies are still undetectable.
This phenomenon may depend on the inter-individual
difference mounting a humoral immune response against
JC virus or on the 2.5% of false negative estimated for the
STRATIFY JCV® test [23]. However, to date these obser-
vations were not replicated in other analyses [25]. Con-
versely, JCPyV DNA in plasma or PBMCs may not be
useful in PML risk stratification. It was debated whether
the detection of JCPyV in blood results in a higher likeli-
hood to develop PML, but it was often observed that
JCPyV DNA can be detected in blood in healthy indivi-
duals and that the JCPyV load in blood is usually very low
even in patients with PML diagnosis [45]. Moreover, no
PML cases have ever been reported in JCPyV seronegative
individuals [14], and the estimated PML incidence in
JCPyV seronegative patients is extremely low (0.09 cases
per 1000 patients) [12]. Thus, humoral immunity alone
seems to be not able to control JCPyV replication [46] as
well as cellular immunity, since JCPyV shedding in urine
of immunocompetent individuals is very common [40].
Although our results were obtained in a small cohort of
patients and need to be replicated and expanded, they
suggest that JCPyV replication with shedding in urine
could be not necessarily a sign of T cell dysfunction, but
instead reflects differences in anatomic location and/or ac-
cessibility to T cells, as other authors also suggested [25].
Finally, in CD patients we observed that the number
of patients with JC viremia and/or viruria remains con-
stant during the follow-up, but comparing the urinary
JCPyV loads obtained at every time of follow-up, we
observed that viruria significantly increased in patients
treated with infliximab at t3 respect to the value
obtained at t0 (p=0.03). This result puts in highlight a
higher viral replication in the renal tubular epithelial
cells with a shedding of the virus in the urine after 1
year of infliximab treatment. Moreover, a constant JC
viral load value was found in intestinal biopsies during
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implicated in JCPyV reactivation directly, it seems to
interfere with the fine balance between the anti-
inflammatory activity of this biologic and the host
immune surveillance [33]. Since the use of infliximab in
CD patients blocks the TNF and interferes with the
recruitment of lymphocytes causing a decreasing of
interferon (IFN)-γ levels involved in the anti-viral state
control, JCPyV could leave its latent state within the
enteric glial cells [47] and could infect the intestinal
epithelium. Furthermore in patients affected by immune-
mediated diseases and treated whit biologics, JCPyV
reactivation has been observed to be associated with
increased plasmatic levels of monokine induced by IFN-γ
(MIG), which represents a T cell-attracting chemokine
released by eosinophils [48,49]. Conversely, JCPyV could
also restart its lytic cycle in other cell types, including the
CD34+ haematopoietic precursors, the B cells present in
BM and in circulation [50] and the renal tubular epithelial
cells [51,52]. This hypothesis could also be supported by
the fact that the median viremia reached the value of 5.30
log gEq/mL in the patients treated with infliximab at t1,
when the drug achieved its highest effectiveness. Finally,
regarding all intestinal biopsies examined, we can hypo-
thesize that JCPyV may undergo reactivation in the gut
with a spreading of virions in the bloodstream, according
to Selgrad and collegues who speculated that this neu-
rotropic virus may switch its latent state in the enteric
neurons on an active lytic infection [47].
The interfering of infliximab in the regulation of the
fine balance between anti-inflammatory drug benefit and
immune surveillance, was also evidenced by the rearran-
ged NCCR sequences found at t3 and t4 in plasma
samples and intestinal biopsies of 7 infliximab-treated
CD patients, who showed a PCDAI value >40 at t0. The
main part of these sequences showed a CY NCCR struc-
ture (Type IIS) with two nucleotide changes, the 37
G→A in the Spi-B binding site and the 217 G→A in the
boxF, whereas other 5 sequences showed a JCPyV NCCR
structure Type IIR characterized by the two nucleotide
changes mentioned above, and a 66bp insert deletion.
Moreover, a rearranged JCPyV NCCR sequence Type IR,
composed by repeats of truncated 98bp unit, was found
at t4 (after 16 months of infliximab treatment) in 2
colon rectal biopsies collected from 2 of the 7 patients
indicated above. Conversely, the rearrangement found in
PBMC samples of MS patients, treated with natalizumab
and resulted STRATIFY JCV® positive t0 and t3, under-
lines the role of these cells into delivering JCPyV
rearranged forms until the brain throughout the blood
stream. In fact, these rearranged NCCR (type IIR)
showed a duplication of a 98 bp unit and a 66 bp insert,
resulting in a boxB deletion with a 37 T→G nucleotide
change into the Spi-B binding site. All these rearrangedform could result neuro-invasive and they could increase
the risk of PML onset in patients treated with biologics:
in fact, we found the rearranged JCPyV NCCR sequen-
ces after 16 months of infliximab and 1 year of natalizu-
mab, respectively. This hypothesis could be supported
by the fact that natalizumab could mobilize CD34+
hematopoietic precursors and B cells, harboring JCPyV
in a latent state, and that Spi-B expression in these cells
could enhance the JCPyV NCCR rearrangement. In par-
ticular we observed that the 37 T→G nucleotide change
shifted the typical CY archetype Spi-B binding site (5′-
AAAAGGGAAGGTA-3′) to the characteristic one of
the PML-associated variant Mad-1 (5′-AAAAGGGAA
GGGA-3′). The finding of this nucleotide change could
enhance JCPyV replication because it has been demon-
strated that, the Spi-B-binding sites that actively bind
the Spi-B protein expressed in JCPyV susceptible cell
types, are present in Mad-1 NCCR sequences, but not in
the non-pathogenic archetype CY [53]. Additionally,
Spi-B have been shown to be up-regulated in glial cells,
B cells and hematopoietic progenitor cells in which
JCPyV can replicate [54]. Spi-B binding sites in the pro-
moter/enhancer of JCPyV variants are located directly
adjacent to TATA boxes that are essential for the
transcription of early and late viral genes. Recruitment
of the transcription complex TFIID to JC viral promoters
by Spi-B is an attractive model for the activation of
JCPyV gene expression in the absence of TAg protein
[55,56]. Furthermore, the shift of the typical CY arche-
type Spi-B binding site in the characteristic one of the
PML-associated variant Mad-1, in association with the
boxD deletion in 5 intestinal biopsies, let us to conclude
that JCPyV is attempting to enhance its virulence espe-
cially in those cells, such as intestinal cells, that are not
permissive to JCPyV replication. These results were
more emphasized by the JCPyV NCCR Mad-1-like type
IR sequence found in two colon-rectal biopsies, in which
an attempt to recombination could have taken place
during virus replication. This last rearrangement could
be also favored both by the unbalanced immunological
state of these patients and by the 16 months of
infliximab treatment. However, the 78% of sequences
isolated from the three Cohorts enrolled, including all
sequences collected from urine samples, showed a CY
archetype NCCR structure (Type IIS), with a 217 G→A
in the boxF. This point mutation is completely in agree-
ment with other literature data: in fact, this nucleotide
change seems to be a common feature of the European
strains as just described by Agostini and colleagues [6].
Moreover, we also observed a prevalence of genotypes
1A and 1B among all patients enrolled, without a JCPyV
strains co-infection in the same patient. In particular, in
the 2 MS patients with a rearranged NCCR sequence
type IIR in the PBMCs, we found the JCPyV Type 1A
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was observed in the two patients with the rearranged
NCCR sequence type IR in colon rectal biopsies.
Although other author found a significant association
between the JCPyV Type 2 and infliximab treatment in a
pediatric CD cohort [57], we did not observed a corre-
lation between rearranged JCPyV NCCR sequences and
a particular JCPyV genotype in each enrolled cohort.
Conversely, all genotypes isolated were in agreement with
the most common genotypes detected in the European
population [6,58].
However, future analyses of alterations and acquisi-
tions of unique transcription factor-binding sites will
probably offer more insight into the role of these factors
in viral pathogenesis. Moreover, B cells have been shown
to support the low levels of JCPyV infection and are
likely carriers of infectious virus to the brain during
reactivation and dissemination, leading to the develop-
ment of PML [32]. Thus, the further study of activation
of Spi-B gene expression in transitional B cells that
contain latent virus may be important to understand the
real role of viral reactivation in PML pathogenesis.
Conclusions
The mechanism underlying JC viral replication are
nevertheless still unknown, and the influence of natali-
zumab on JCPyV control is unclear. However, from these
preliminary data we can conclude that it is important to
understand whether the specific inflammatory scenario
in different immune-mediated diseases could affect the
JC virus reactivation from its sites of latency. In parti-
cular, an imbalance of cell-mediated immunity may have
led to a JCPyV urinary shedding significantly higher in
patients with CIRDs at t0 respect to MS and CD
patients. Moreover, for a more accurate PML risk strati-
fication in patients treated with natalizumab, testing
JCPyV viruria seems to be useful to identify patients
who harbor JCPyV but with an undetectable JCPyV-
specific humoral immune response. Moreover, since the
number of CD patients treated with infliximab showed a
JC viruria higher than that observed in patients with MS
during the follow-up, we could suppose that infliximab
encourages JCPyV reactivation respect to natalizumab.
For a better risk stratification in patients treated with
biologics, it may also be important to study the JCPyV
NCCR genomic regions. In particular, the rearrangement
found in the PBMCs of MS patients treated with
natalizumab underlying the role of these cells into
delivering JCPyV rearranged forms until the brain
throughout the blood stream. These rearranged form
could result neuro-invasive and they could increase the
risk of PML onset in patients treated with natalizumab.
This is supported by the fact that natalizumab could
mobilize CD34+ hematopoietic precursors and B cells,harboring JCPyV in a latent state, and that Spi-B expres-
sion in these cells could enhance the JCPyV NCCR rear-
rangement. It’s important to understand the molecular
mechanisms involved in JCPyV latency and reactivation
in peripheral blood cells, because they represents the
main pieces in the puzzle of PML pathogenesis.
Moreover, infliximab could also be implicated into the
mobilization of CD34+ hematopoietic precursors and B
cells, harboring JCPyV in a latent state, although an
evident risk of PML onset after the use of this drug was
not observed [50]. Conversely, the issue of JCPyV NCCR
rearrangement in non-permissive cells, such as intestinal
cells in patients with CD treated with infliximab, and its
association with cancer is emerging [1]. This obsarvation
could be a great starting point to explore the possible JC
virus role in in the pathogenesis of colon cancer, consi-
dering also the nature of Polyomaviruses, the oncogenic
viruses par excellence. Finally, we can highlight that our
rearranged NCCR sequences could be considered a
marker of the JCPyV virulence during the mAb treat-
ment, although none of our examined patients devel-
oped PML, and further studies on larger cohorts should
be performed. In conclusion, since the number of pa-
tients affected by autoimmune disease and treated with
biological agents, continues to rise [59], we could take
into account that the follow-up of JCPyV DNA detection
and the subsequent JCPyV NCCR sequences analysis
may be important in order to reduce the risk of PML
onset. Further investigation into the molecular inter-
actions that occurs between Spi-B, protein cofactors,
and the JCPyV NCCR in cells that support latent infec-
tion will offer additional insight into molecular patho-
genesis, reactivation from latency in lymphocytes and
PML development. Finally, in individuals treated with
immunomodulatory drugs, an impairment of the immu-
ne surveillance could be an important risk factor for the
JCPyV reactivation and the PML onset. Therefore, it is
important to focus all our efforts to find the cellular
pathways, finely regulated by the host immune system,
that lead to the reactivation of the virus in conditions of
immunosuppression, since it is virtually impossible to
control the JCPyV infection.
Methods
Enrolled patients features and study schedule
In this perspective observational study, three dynamic
cohorts of autoimmune diseases patients were enrolled:
1. Twenty-one outpatients with a diagnosis of MS
(11 males, 10 females) (Cohort1) were enrolled at
the Department of Neurology and Psychiatry
(Sapienza University of Rome, Italy) between March
2012 to April 2013. Patient’s mean age (± standard
deviation) was 35.05 ± 8.12 years; mean disease
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Expanded Disability Status Scale (EDSS) at
enrollment of 2.05 ± 1.07. Among the 21 patients,
13 (62%) previously underwent immunomodulating
therapies (interferon, glatiramer acetate); 1 patient
(5%) was treated with immunosuppressive drugs
(mitoxantrone) and the other 7 (33%) individuals
were not previously treated at all. No significant
differences were observed concerning the type of
previous therapy and disease duration. All patients
fulfilled the Italian Agency of Drug criteria for
natalizumab treatment, i.e. they either were affected
by a particularly severe disease course in the year
prior to therapy (marked clinical worsening, high
relapse rate, rapid disability accumulation),
or they showed a lack of response to previous
immunosuppressive or immunomodulatory
therapies. The therapeutic program of the
patients of this cohort consisted of 300 mg
intravenous (IV), infused over approximately 1 hour,
every 4 weeks (1 infusion a month). 78 urine,
78 plasma and 78 PBMCs samples were collected at
baseline (t0) and after 4 (t1), 8 (t2), and 12 (t3)
months of therapy. Only for Cohort1, after the
activation of a centralized service supported by
Biogen Idec (STRATIFY JCV®), 2-step virus-like
particle-based enzyme-linked immunosorbed
assay (ELISA) was performed at t0 and t3,
to detect specific anti-JC virus antibodies [23] in
serum of the 21 enrolled subjects treated for a
12-month period.
2. Twenty-two outpatients affected by CIRDs
(7 males, 15 females) (Cohort2), referred to the
Department of Internal Medicine and Medical
Disciplines, Rheumatology Unit (Sapienza University
of Rome, Italy), were enrolled from January 2013 to
April 2013. After obtaining informed consent, basic
demographic data including gender, age, diagnosis,
date of diagnosis, concomitant medications and
disease activity measures were collected at a single
time point, just before the initiation of biologic
therapy and recorded on a standardized form
(Table 2). Patient’s mean age (± standard deviation)
was 54.68 ± 10.79 years and mean disease duration
was 112.82 ± 97.44 months. Patients with RA, PsA,
and AS, classified according to standard criteria
[60-62] and designated to start biologic treatment,
were consecutively enrolled. Each patient was
evaluated by the same rheumatologist. For RA and
PsA clinical evaluation included: swollen (SJC) and
tender joint count (TJC), patient and physician
global assessment on a visual analogue scale
(VAS, 0-100 mm), and HAQ [63]. The HAQ scores
range from 0-3, with a higher score indicating ahigher level of disability [64]. A blood drawing
was also performed to evaluate ESR (mm/h) and
CRP (mg/l). Disease activity was assessed by the
DAS28-CRP and/or the DAS28-ESR, with a high
score indicating more active disease [63].
Current disease activity in patients with AS
was measured by the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI),
ranging from 0 (no activity) to 10 (maximum
activity) [65]. 22 urine, 22 plasma and
22 PBMCs samples collected only at baseline
(t0) were utilized to compare the baseline
JCPyV DNA quantitative detection in each samples
type of these individuals with those of MS and
CD patients.
3. Eighteen patients (10 males, 8 females; mean age ±
standard deviation: 14.61 ± 4.36 years) (Cohort3) with
refractory active CD and thus aimed at infliximab
treatment, referred to the Pediatric Gastroenterology
and Liver Unit (Sapienza University of Rome, Italy)
from January 2010 to December 2012, were enrolled.
Inclusion criteria were: CD diagnosis confirmed with
usual clinical, endoscopic, radiologic, and/or histologic
criteria for at least 6 months; and active luminal or
fistulizing disease despite adequate standard
treatments. Exclusion criteria were contraindications
to infliximab treatment, such as a history of
tuberculosis or positive skin test/chest radiogram in
the absence of adequate antibiotic prophylaxis,
congestive heart failure, demyelinating syndrome,
sepsis or abscesses, symptomatic bowel stenoses,
history of previous or present cancer, or failure to give
informed consent. After enrollment, clinical
characteristics of CD disease were recorded, clinical
activity was measured with the Pediatric CD Activity
Index (PCDAI) [66], collected retrospectively during
the visit immediately before infusions according to the
Frenz et al. protocol [67], and fistula were assessed
according to the Present et al. [68] assessment system.
The therapeutic program of the patients of this cohort
consisted of three consecutive infusions of infliximab
(5 mg/kg) at 0, 2, and
6 weeks for the induction phase. The first infusion
was given within 7 days of enrollment into the study.
Infliximab was administered intravenously during a
period of 2 h, and patients were monitored for heart
frequency and for signs of adverse reactions. From
each patient, blood samples were taken before
infusion, after 8 weeks the beginning of therapy and
every 8 weeks thereafter, to determine the activity and
nutritional indexes as well as serum variables of renal
and hepatic function. All patients were offered a
maintenance therapeutic program consisting of
repeated infusions of infliximab every
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infusion was administrated 8 weeks after the last
baseline infusion. Clinical effectiveness was evaluated
at week 6: remission was defined by a PCDAI score
of less than 10 (for luminal disease) or if all fistulae
openings present at baseline were closed
(for fistulizing disease). Improvements were
determined based on the physician's global evaluation
of amelioration compared with baseline [69]. We
collected 90 plasma and 90 urine samples from these
patients at the following times: recruitment (t0) and at
4, 8, 12 and 16 months from t0 (t1, t2, t3, and t4,
respectively). PBMCs samples were not collected in
this Cohort because of the small amount of available
whole blood. Moreover,
54 ileal and 54 colon–rectal biopsies were collected at
t0, t3 and t4.
4. Finally, we enrolled 19 healthy individuals
(9 male, 10 females; mean age ± standard deviation:
35.94 ± 6.56 years) (Control Cohort) as control
group. For the Control Cohort, 19 urine,
19 plasma and 19 PBMCs samples were obtained
from healthy individuals, only at the moment
of enrollment (t0).Clinical specimens processing and JCPyV DNA extraction
This study was carried out on a total of 186 plasma, 186
urine and 96 PBMCs samples and 108 intestinal biopsies
collected at different times from the three cohort as
mentioned above. DNA for molecular analysis was
extracted from 500 μl of each urine sample, collected
without preservatives, using the DNeasy® Blood & Tissue
Kit (QIAGEN, S.p.A, Italy) according to the manu-
facturer’s instructions and stored at -20°C until use.
Blood samples, collected in 4-mL Vacuntainer® tubes
containing EDTA (BD Becton Dickinson S.p.A, Italia),
were centrifuged at 1,376 g/sec for 10 minutes and DNA
was extracted from 200 μL of plasma using the DNeasy®
Blood & Tissue Kit (QIAGEN, S.p.A, Milan, Italy) and
stored at -20°C until use. Peripheral blood mononuclear
cells (PBMCs) were isolated from whole blood using
the standard Ficoll Hypaque density gradient centri-
fugation technique [70]; the number of viable leu-
kocytes was determined by trypan blue exclusion.
PBMCs DNA extraction was performed on 106 cells
by the QIAmp® DNA Blood Kit (QIAGEN S.p.A,
Milan, Italy) according to the manufacturer’s instruc-
tions and DNA was stored at -20°C until use. DNA
yield of all samples was determined by measuring its
concentration in the eluate by absorbance at 260 nm
and then 0.1-1 μg of total DNA was directly used for
PCR amplification assays.JCPyV T-Ag real-time PCR (Q-PCR)
Extracted DNA of each samples was analyzed using Q-
PCR for the detection and quantification of the JCPyV
genome using a 7300 Real-Time PCR System (Applied
Biosystems, USA), following a published protocol [71].
Of DNA, 500 ng was used as a template in each reac-
tion, and a 54-bp amplicon in the JCPyV T antigen
region was detected. Each sample was analyzed in dupli-
cate, and the viral load results were given as the mean of
the two positive reactions. Each run contained a negative
control composed of the reaction mixture without DNA
template. A positive control consisted of serial dilutions
(range, 105 gEq/ml–102 gEq/ml) of a plasmid containing
the entire JCPyV genome, on the results of which a
standard curve was performed. For urine and plasma
specimens, the JCPyV DNA load was expressed as
genome equivalents (gEq)/ml of sample and as genome
equivalents (gEq)/106 cells of sample for the biopsies. To
correct for the variable amount of DNA in different
tissue samples, each sample was subjected to simulta-
neous TaqMan PCR for the housekeeping gene Glyceral-
dehyde-3-phosphate-dehydrogenase (GAPDH, Accession
no. J04038), targeting the region between exons 6 and 8.
Results were considered acceptable only in the presence
of GAPDH positivity [72].
JCPyV NCCR PCR
DNA yield was determined by measuring its concentra-
tion in the eluate by absorbance at 260 nm, and then, 0.1
to 1 μg of total DNA was directly used in PCR amplifica-
tion. β-globin PCR was performed on extracted DNA to
assess the efficacy of nucleid acid extraction [73]. General
precautions, conditions for PCR analysis, and nested-PCR
procedures were performed as published [74]. β-Globin
-positive samples were amplified in a GeneAmp® PCR
System 9700 (Perkin-Elmer Cetus, Emeryville, CA), and
all assays included positive (purified recombinant plasmid
DNA) and negative (all the PCR components except the
template) controls to exclude false-positive and false-
negative results [75]. Nested-PCR employed two pairs of
primers that anneal to the invariant regions flanking the
NCCR of JCPyV [74]. Primers BKTT1 (5′-AAG GTC
CAT GAG CTC CAT GGA TTC TTC C-3′) and BKTT2
(5′-CTA GGT CCC CCA AAA GTG CTA GAG CAG C-
3′) amplified a 724-bp DNA fragment in JCPyV (Mad-1)
[76]. The second pair, JC1 (5′-CCT CCA CGC CCT TAC
TAC TTC TGA G-3′) and JC2 (5′-AGC CTG GTG ACA
AGC CAA AAC AGC TCT-3′), amplified a portion of
the first round PCR product, generating a fragment of 308
bp [77]. Two nanograms of recombinant pGem-1 plasmid
DNA containing the complete JCPyV genome, cloned as
EcoR1 fragments, were used as positive controls. The PCR
products were analyzed on 2% agarose gels by ethidium
bromide staining.
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For JCPyV genotyping a 215 bp fragment was amplified
from the VP1 major capsid protein gene using primers
JLP-15 (5′-ACA GTG TGG CCA GAA TTC ACT ACC-
3′) and JLP-16 (5′-TAA AGC CTC CCC CCC AAC
AGA AA-3′) [6]. After initial denaturation at 95°C for 9
min, followed by 40 cycles at 95°C for 40 s, annealing at
63°C for 40 s and extension at 72°C for 40 s, the ampli-
fication protocol was concluded with a final extension at
72°C for 7 min. PCR products were analyzed using 2%
agarose gel electrophoresis and visualized using ethi-
dium bromide staining [54].
Sequencing of JCPyV NCCR and VP1 regions
The PCR product corresponding to JCPyV NCCR and
VP1 regions were purified prior to sequencing to remove
the excess of primers with QIAquick PCR purification
kit, according to QIAGEN protocol [74]. DNA sequen-
cing was performed by automatic DNA sequencer
(Applied Biosystem, model 370 A), according to the
manufacturer′s specifications (Amplicycle Kit, Applied
Biosystem). Sequences were organized and analyzed
using the Genetic Computer Group Sequence Analysis
software package. In particular, all sequences obtained
from the amplification of the NCCR region were
compared to the JCPyV NCCR sequence of prototype
Mad-1 (GenBank: J02227) [36] and of archetype CY
[38], whereas those obtained from the amplification of
the VP1 region were classified into known genotype/
ssubtype analysing the single nucleotide polymorphisms
(SNPs) within the amplified VP1 region. To detect the
SNPs, by which we have classified our isolates, we
aligned our isolated with those reported by Jobes and
colleagues in 2001 [78].Sequence alignments were per-
formed with ClustalW2 at the EMBL-EBI website using
default parameters [79].
Data analysis
Data were summarized as medians and ranges or as
mean ± standard deviation, as appropriate. If Z test indi-
cated a non-normal distribution, we used non-parametric
tests such as Mann–Whitney U test and Kruskal–Wallis
test. Categorical data were analyzed by using χ2 test and
Student's t test. P values <0.05 were considered statisti-
cally significant.
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